Study drug for swelling from advanced liver scarring
Part of Digestive system clinical trials.
This Phase 2 trial tests OsrHSA in people with advanced cirrhosis who have swollen belly fluid (ascites). It aims to see whether the treatment can improve outcomes in this difficult liver condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must understand the study and agree to sign the consent form
- You have advanced cirrhosis with belly fluid (ascites), confirmed by exam, blood tests, or scans
- Your blood albumin level must be low (30 g/L or less)
- You must have a usable vein for study treatment
- If you can become pregnant, you must use strict birth control and have a negative pregnancy blood test before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether high-dose albumin can reduce “refractory ascites,” which is fluid buildup in the belly that doesn’t improve with the highest tolerated water pills (diuretics). If you have liver cirrhosis and need frequent drainage, this study may offer a new treatment option.
This trial tests whether a personalized long-term albumin (a blood protein medicine) can help people with advanced liver scarring who have fluid in the belly (ascites). It compares the personalized albumin approach to standard care to see if it improves outcomes over time.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Hear when a new Cirrhotic Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.